Low ‐dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti‐thymocyteglobulin

ConclusionsThe hybrid strategy with low‐dose VGCV in R+ patients with ATG was efficient and safe. The good treatment results indicate that the regimen did not lead to a clinically relevant resistance. Optimal renal dosage is essential throughout prophylaxis.This article is protected by copyright. All rights reserved.

Source: Transplant Infectious Disease - March 7, 2018 Category: Transplant Surgery Authors: Mari Eriksson, Janne J. Jokinen, Sanni S öderlund, Pekka Hämmainen, Jyri Lommi, Karl B Lemström Tags: Original Report Source Type: research